Cardiac Resynchronization Therapy for Heart Failure

  • Mumin R. Noor
  • Rebecca E. Lane
  • Owais DarEmail author


Cardiac resynchronization therapy (CRT) is an effective treatment for selected patients with chronic heart failure and a prolonged QRS interval. In combination with the pharmacotherapy, it is one of the most powerful recent advances for reducing morbidity and mortality in the challenging heart failure population. The goal of CRT is to restore mechanical synchrony by electrically activating the heart in a synchronized manner in patients with severe systolic left ventricular (LV) dysfunction and a widened QRS. CRT results in both short-term and long-term improvement in cardiac structure and function, leading to enhanced quality of life and, for some populations, enhanced survival. Ongoing and future research will continue to investigate ways to reduce the frequency of non-response to CRT while seeking to expand the pool of patients eligible for this life-saving therapy.


Cardiac resynchronization therapy Chronic heart failure Electromechanical dyssynchrony Mechanical synchrony 


  1. 1.
    Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129–200.CrossRefGoogle Scholar
  2. 2.
    Cowie MR, Mosterd A, Wood DA. The epidemiolohgy of heart failure. Eur Heart J. 1997;18:208–25.CrossRefGoogle Scholar
  3. 3.
    Thomas T, Haase N, Rosamond W. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–151. Erratum in: Circulation 2006;113:e696.Google Scholar
  4. 4.
    Bleumink GS, Knetsch AM, Sturkenboom MC. Quantifying the heart failure epidemic: prevalence, incidence rate, life time risk and prognosis of heart failure. The Rotterdam study. Eur Heart J. 2004;25:1614–9.CrossRefGoogle Scholar
  5. 5.
    Hobbs F, Kenkre J, Roalfe A. Impact of heart failure and left ventricular systolic dysfunction on quality of life. Eur Heart J. 2002;23:1867–76.CrossRefGoogle Scholar
  6. 6.
    Clark AL, Goode K, Cleland JG. The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure. Eur J Heart Fail. 2008;10:696–702.CrossRefGoogle Scholar
  7. 7.
    Bakker PF, Meijburg HW, de Vries JW. Biventricular pacing in end-stage heart failure improves functional capacity and left ventricular function. J Interv Card Electrophysiol. 2000;4:395–404.CrossRefGoogle Scholar
  8. 8.
    Cazeau S, Leclercq C, Lavergne T. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873–80.CrossRefGoogle Scholar
  9. 9.
    Abraham WR, Fisher WG, Smith A. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845–53.CrossRefGoogle Scholar
  10. 10.
    Bristow MR, Saxon LA, Boehmer J. Cardiac- resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.CrossRefGoogle Scholar
  11. 11.
    Cleland JG, Daubert JC, Erdmann E. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.CrossRefGoogle Scholar
  12. 12.
    Moss AJ, Hall WJ, Cannom DS. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–38.CrossRefGoogle Scholar
  13. 13.
    Tang AS, Wells GA, Talajic M. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–95.CrossRefGoogle Scholar
  14. 14.
    Linde C, Abraham WT, Gold MR. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834–43.CrossRefGoogle Scholar
  15. 15.
    Cleland JG, Abraham WT, Linde C. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34:3547–56.CrossRefGoogle Scholar
  16. 16.
    Ruschitzka F, Abraham WT, Singh JP. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369:1395–405.CrossRefGoogle Scholar
  17. 17.
    Steffel J, Robertson M, Singh JP. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J. 2015;36:1983–9.CrossRefGoogle Scholar
  18. 18.
    Tracy CM, Epstein AE, Darbar D. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2012;60:1297–313.CrossRefGoogle Scholar
  19. 19.
    Jaffe LM, Morin DP. Cardiac resynchronization therapy: history, present status, and future directions. Ochsner J. 2014;14:596–607.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Noheria A, Desimone CV, Lachman N, et al. Anatomy of the coronary sinus and epicardial coronary venous system in 620 hearts: an electrophysiology perspective. J Cardiovasc Electrophysiol. 2013;24:1–6.CrossRefGoogle Scholar
  21. 21.
    Butter C, Gras D, Ritter P, et al. Comparative prospective randomized efficacy testing of different guiding catheters for coronary sinus cannulation in heart failure patients. J Interv Card Electrophysiol. 2003;9:343–51.CrossRefGoogle Scholar
  22. 22.
    Scheffer M, van Gelder BM. Implantation techniques of leads for left ventricular pacing in cardiac resynchronization therapy and electrocardiographic consequences of the stimulation site. In: Millis R, editor. Advances in electrocardiograms – methods and analysis. London: IntechOpen; 2012. p. 53–80.Google Scholar
  23. 23.
    Butter C, Auricchio A, Stellbrink C, et al. Effect of resynchronization therapy stimulation site on the systolic function of the heart failure patients. Circulation. 2001;104:3026–9.CrossRefGoogle Scholar
  24. 24.
    Antonini L, Auriti A, Pasceri V, Meo A, Pristipino C, Varveri A, Greco S, Santini M. Optimization of the atrioventricular delay in sequential and biventricular pacing: physiological bases, critical review, and new purposes. Europace. 2012;14:929–38.CrossRefGoogle Scholar
  25. 25.
    Brabham WW, Gold MR. The role of AV and VV optimization for CRT. J Arrhythm. 2013;29:153–61.CrossRefGoogle Scholar
  26. 26.
    van Rees JB, de Bie MK, Thijssen J, Borleffs CJW, Schalij MJ, van Erven L. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. J Am Coll Cardiol. 2011;58:995–1000.CrossRefGoogle Scholar
  27. 27.
    Leon AR, Abraham WT, Curtis AB, Daubert JP, Fisher WG, Gurley J, Hayes DL, Lieberman R, Petersen-Stejskal S, Wheelan K. Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure: combined results of over 2,000 patients from a multicenter study program. J Am Coll Cardiol. 2005;46:2348–56.CrossRefGoogle Scholar
  28. 28.
    Leclercq C, Gadler F, Kranig W. A randomized comparison of triple-site versus dual-site ventricular stimulation in patients with congestive heart failure. J Am Coll Cardiol. 2008;51:1455–62.CrossRefGoogle Scholar
  29. 29.
    Auricchio A, Delnoy PP, Regoli F, et al. First-in-man implantation of leadless ultrasound-based cardiac stimulation pacing system: novel endocardial left ventricular resynchronization therapy in heart failure patients. Europace. 2013;15:1191–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Transplantation and Mechanical Circulatory Support, Harefield HospitalRoyal Brompton and Harefield NHS TrustLondonUK

Personalised recommendations